NEWS Oct.10 2023 SAFE's participation in "Targeting and Cytotoxicity of Chimeric Antigen Receptor T Cells Transplanted with PD1 Extramembrane Structural Domains" is officially in press Oct.10 2023 SAFE's participation in " The repeated administration of rhIL-12 for 14 weeks in rhesusmonkeys: A toxicity assessment" is officially in press Mar.19 2023 Navigating the Global NHP Shortage Dec.02 2022 SAFE Pharmaceutical Completes 500 Million Yuan D Funding Round Jun.09 2022 SAFE Pharmaceutical Announces New Scientific Advisory Board Appointment